| [1] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol，2018，19(1): 27-39.
|
| [2] |
Echeverria GV, Ge Z, Seth S, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state[J]. Sci Transl Med, 2019，11(488): eaav0936.
|
| [3] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6): 394-424.
|
| [4] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021，71(3): 209-249.
|
| [5] |
Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats[J]. Biochem Biophys Res Commun，1984，122(3): 1450-1459.
|
| [6] |
张钊，何平，张树琦，等. 微卫星不稳定性和肝细胞生长因子对结直肠癌患者生存状况的影响[J/CD]. 中华普外科手术学杂志(电子版), 2017，11(5): 439-442.
|
| [7] |
Moosavi F, Giovannetti E, Saso L, et al. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers[J]. Crit Rev Clin Lab Sci, 2019，56(8): 533-566.
|
| [8] |
Pothula SP, Xu Z, Goldstein D, et al. Targeting HGF/c-MET Axis in Pancreatic Cancer[J]. Int J Mol Sci, 2020，21(23): 9170.
|
| [9] |
Aliebrahimi S, Kouhsari SM, Ostad SN，et al. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies[J]. Cell Biochem Biophys，2018，76(1-2): 135-145.
|
| [10] |
Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy[J]. Nat Rev Cancer, 2018，18(6): 341-358.
|
| [11] |
Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review[J]. Breast Cancer Res, 2015，17(1): 52.
|
| [12] |
李传书，葛述科，高伟，等. 大连市不同型别乳腺癌患者的临床病理特征与生存状况研究[J/CD]. 中华普外科手术学杂志(电子版)，2020，14(3): 268-272.
|
| [13] |
Xu Z, Zhu C, Chen C, et al. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1alpha/VEGF-A pathway in colorectal cancer[J]. Cell Death Dis, 2018，9(10): 974.
|
| [14] |
Qiu SQ, van Rooijen J, Nienhuis HH, et al. High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer[J]. Breast Cancer Res, 2020，22(1): 30.
|
| [15] |
刘海旺，张宏旭，刘燃，等. HGF、E-cad蛋白在乳腺癌组织中的表达及其临床意义[J]. 解放军预防医学杂志，2019，37(12): 7-8.
|
| [16] |
崔志超 马杰 王雅琪，等. HER2阳性乳腺癌患者新辅助化疗后免疫分型变化的研究[J/CD]．中华普外科手术学杂志(电子版)，2020，14(2): 189-192.
|